Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
25 mars 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of two new...
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
24 mars 2021 16h01 HE
|
Abeona Therapeutics Inc.
Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA Positive new interim data from MPS IIIA and MPS IIIB programs presented at 17th...
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
22 mars 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso,...
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
22 févr. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present...
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
12 févr. 2021 11h36 HE
|
Abeona Therapeutics Inc.
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained...
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
02 févr. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live...
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
25 janv. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company held a...
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
21 déc. 2020 12h20 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new...
Abeona Therapeutics Reports Third Quarter Financial Results
09 nov. 2020 16h05 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the third...
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
27 oct. 2020 06h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior...